Contract Services
Fujifilm to invest $90 million in CDMO business for biologics 9th January 2019
Fujifilm Corporation has announced plans to invest approximately $90 million to expand its bio contract development and manufacturing organization (CDMO) business, Fujifilm Diosynth Biotechnologies (FDB). This investment will include the expansion of existing production facilities at its North Carolina location to support the growing needs of its customer portfolio. Additional investments are planned at the company’s other locations; details will be announced in the first quarter of 2019.
Fujifilm is investing in FDB’s facilities to increase production capacity to meet its growing customer demands. This new round of investments will include the addition of 2000L single use cell culture manufacturing trains, cell culture purification suites and new microbial recovery suites to its existing facilities in North Carolina. These additions will increase cell culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50% at its North Carolina location. The company expects that the increased production capacity will be ready for cGMP manufacture by early 2020.
“We provide high-quality products and services through leading-edge, proprietary technologies in various fields,” said Takatoshi Ishikawa, director, senior vice president, general manager, bio CDMO division, Fujifilm Corporation. “Fujifilm is dedicated to supporting the biologics industry by providing flexible manufacturing capacity that supports our clients in getting medicines to patients.”
Fujifilm is investing in FDB’s facilities to increase production capacity to meet its growing customer demands. This new round of investments will include the addition of 2000L single use cell culture manufacturing trains, cell culture purification suites and new microbial recovery suites to its existing facilities in North Carolina. These additions will increase cell culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50% at its North Carolina location. The company expects that the increased production capacity will be ready for cGMP manufacture by early 2020.
“We provide high-quality products and services through leading-edge, proprietary technologies in various fields,” said Takatoshi Ishikawa, director, senior vice president, general manager, bio CDMO division, Fujifilm Corporation. “Fujifilm is dedicated to supporting the biologics industry by providing flexible manufacturing capacity that supports our clients in getting medicines to patients.”
